Molecular Cytogenetic Profiling Reveals Similarities and Differences Between Localized Nodal and Systemic Follicular Lymphomas

Recently, we have developed novel highly promising gene expression (GE) classifiers discriminating localized nodal (LFL) from systemic follicular lymphoma (SFL) with prognostic impact. However, few data are available in LFL especially concerning hotspot genetic alterations that are associated with the pathogenesis and prognosis of SFL. A total of 144 LFL and 527 SFL, enrolled in prospective clinical trials of the German Low Grade Lymphoma Study Group, were analyzed by fluorescence in situ hybridization to detect deletions in chromosomes 1p, 6q, and 17p as well as BCL2 translocations to determine their impact on clinical outcome of LFL patients. The frequency of chromosomal deletions in 1p and 17p was comparable between LFL and SFL, while 6q deletions and BCL2 translocations more frequently occurred in SFL. A higher proportion of 1p deletions was seen in BCL2-translocation–positive LFL, compared with BCL2-translocation–negative LFL. Deletions in chromosomes 1p, 6q, and 17p predicted clinical outcome of patients with SFL in the entire cohort, while only deletions in chromosome 1p retained its negative prognostic impact in R-CHOP–treated SFL. In contrast, no deletions in one of the investigated genetic loci predicted clinical outcome in LFL. Likewise, the presence or absence of BCL2 translocations had no prognostic impact in LFL. Despite representing a genetic portfolio closely resembling SFL, LFL showed some differences in deletion frequencies. BCL2 translocation and 6q deletion frequency differs between LFL and SFL and might contribute to distinct genetic profiles in LFL and SFL.

[1]  J. Cerhan,et al.  Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma , 2021, Blood Cancer Journal.

[2]  C. Copie-Bergman,et al.  Follicular lymphoma t(14;18)-negative is genetically a heterogeneous disease. , 2020, Blood advances.

[3]  Jie Zhu,et al.  IL-21 enhances STAT3/Blimp-1 signaling pathway in B cells and contributes to plasma cell differentiation in newly diagnosed patients with myasthenia gravis , 2020, Immunologic Research.

[4]  A. Rosenwald,et al.  Localized and Advanced Stage Follicular Lymphomas Differ in their Gene Expression Profiles. , 2019, Blood.

[5]  W. Klapper,et al.  Progression of Disease Within 24 Months in Follicular Lymphoma Is Associated With Reduced Intratumoral Immune Infiltration , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  A. Rosenwald,et al.  Differences between BCL2-break positive and negative follicular lymphoma unraveled by whole-exome sequencing , 2018, Leukemia.

[7]  J. Cerhan,et al.  A gene-expression profiling score for outcome prediction disease in patients with follicular lymphoma: a retrospective analysis on three international cohorts , 2018, The Lancet. Oncology.

[8]  S. Swerdlow WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues , 2017 .

[9]  R. Kridel,et al.  Genetic and epigenetic inactivation of SESTRIN1 controls mTORC1 and response to EZH2 inhibition in follicular lymphoma , 2017, Science Translational Medicine.

[10]  J. D. van der Walt,et al.  Genome-wide analysis of pediatric-type follicular lymphoma reveals low genetic complexity and recurrent alterations of TNFRSF14 gene. , 2016, Blood.

[11]  A. Rosenwald,et al.  Clinicogenetic risk models predict early progression of follicular lymphoma after first-line immunochemotherapy. , 2016, Blood.

[12]  A. Rosenwald,et al.  Similar clinical features in follicular lymphomas with and without breaks in the BCL2 locus , 2016, Leukemia.

[13]  Takashi Watanabe,et al.  Follicular Lymphoma: The Role of the Tumor Microenvironment in Prognosis. , 2016, Journal of clinical and experimental hematopathology : JCEH.

[14]  Robert Kridel,et al.  Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry. , 2015, The Lancet. Oncology.

[15]  A. Rosenwald,et al.  Numerical and Structural Genomic Aberrations Are Reliably Detectable in Tissue Microarrays of Formalin-Fixed Paraffin-Embedded Tumor Samples by Fluorescence In-Situ Hybridization , 2014, PloS one.

[16]  S. Bens,et al.  Recurrent loss of heterozygosity in 1p36 associated with TNFRSF14 mutations in IRF4 translocation negative pediatric follicular lymphomas , 2013, Haematologica.

[17]  Michael Unterhalt,et al.  The composition of the microenvironment in follicular lymphoma is associated with the stage of the disease. , 2012, Human pathology.

[18]  H. Eich,et al.  Treatment of Early Stage Nodal Follicular Lymphoma Using Involved-Field Radiotherapy and Rituximab: Preliminary Results of the Mir Trial (phase II study of the German Low Grade Lymphoma Study Group (GLSG)) , 2012 .

[19]  K. Tarte,et al.  High rate of TNFRSF14 gene alterations related to 1p36 region in de novo follicular lymphoma and impact on prognosis , 2012, Leukemia.

[20]  Bernhard Puppe,et al.  MicroRNA profiles of t(14;18)-negative follicular lymphoma support a late germinal center B-cell phenotype. , 2011, Blood.

[21]  R. Gascoyne,et al.  Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis. , 2010, Cancer research.

[22]  A. Rosenwald,et al.  A distinctive subtype of t(14;18)-negative nodal follicular non-Hodgkin lymphoma characterized by a predominantly diffuse growth pattern and deletions in the chromosomal region 1p36. , 2009, Blood.

[23]  R. Spang,et al.  Microarray‐based genomic profiling reveals novel genomic aberrations in follicular lymphoma which associate with patient survival and gene expression status , 2009, Genes, chromosomes & cancer.

[24]  L. Staudt,et al.  Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. , 2007, Blood.

[25]  Christian Steidl,et al.  Genome-wide profiling of follicular lymphoma by array comparative genomic hybridization reveals prognostically significant DNA copy number imbalances. , 2009, Blood.

[26]  A. Rosenwald,et al.  Detailed mapping of chromosome 17p deletions reveals HIC1 as a novel tumor suppressor gene candidate telomeric to TP53 in diffuse large B-cell lymphoma , 2008, Oncogene.

[27]  J. Winter Prognostic markers in diffuse large B-cell lymphoma: Keys to the underlying biology , 2007, Current hematologic malignancy reports.

[28]  E. Hoster,et al.  Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas , 2006, Cancer.

[29]  P. Solal-Céligny Follicular Lymphoma International Prognostic Index. , 2004, Current treatment options in oncology.

[30]  N. Schmitz,et al.  Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of t , 2005, Blood.

[31]  D. de Jong Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  L. Staudt,et al.  Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells. , 2004, The New England journal of medicine.

[33]  Ash A. Alizadeh,et al.  Transformation of follicular lymphoma to diffuse large cell lymphoma is associated with a heterogeneous set of DNA copy number and gene expression alterations. , 2003, Blood.

[34]  R. Siebert,et al.  Clinicopathologic correlations of genomic gains and losses in follicular lymphoma. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[35]  Annick,et al.  Prognostic value of chromosomal abnormalities in follicular lymphoma. , 1994, Blood.